



Press Release - For immediate release

Poietis, the 4D Bioprinting company, has been invited to present its technology at the second International Bioprinting Congress at Singapur

Pessac, France, June 08th 2015 – Poietis, first French bioprinting company, announced today its participation to the second International Bioprinting Congress organized in Singapore, July 09 - 10, 2015. Dr. Fabien Guillemot, Founder and President of Poietis, will present Poietis proprietary technology: laser-assisted 3D bioprinting and the concept of 4D.

The conference, organized by SELECTBIO Ltd. is the second edition of the event about the emergence of bioprinting worldwide: <http://selectbiosciences.com/conferences/index.aspx?conf=IBC2015>
"The participation of Poietis to this event is very important for us" commented Bruno Brisson, Co-Founder and VP Business Development. "This is an opportunity for Fabien to present our unique laser-assisted 3D bioprinting technology and its advantages, to talk about our business model with researchers from the pharmaceutical and cosmetic industry, and discuss partnerships opportunities especially with the academic world" .

About Poietis: To meet the growing needs of transplantable human tissues Poietis values the research previously conducted at INSERM and University of Bordeaux on Laser-Assisted 3D Bioprinting, holding the exclusive rights on the technology. The company was founded in September 2014 after two years of maturation of the project in the Aquitaine Regional Incubator.

Laser-Assisted Bioprinting proceeds by layer-by-layer assembly of the constituents of biological tissues according to predefined 3D digital design organizations. This innovative 3D bioprinting technology is unique by its high resolution and the preservation of cell viability. It overcomes the limitations of conventional cell culture and tissue engineering methods, and opens the way for the production of complex tissues - representative of the biological reality - and customizable - representative of a given patient.

Poietis first business model is the development and production of biological tissues for tests conducted in the laboratories of cosmetics and pharmaceutical industries. The second step will be to develop custom-made tissues, specific of a given patient, to select the most appropriate therapy to an individual (companion diagnostics).

Finally Poietis will rely on the expertise developed in the design and development of customized biological tissues to move towards clinical applications in regenerative medicine. The aim of the company is to offer a custom grafts manufacturing service to the growing needs of tissue transplants such as skin and cornea.

Contacts : Poietis, 27 allée Charles Darwin, Bat. C – BioParc Biogalien, 33600 Pessac

Fabien Guillemot : fabien.guillemot@poietis.com

Bruno Brisson : bruno.brisson@poietis.com